CYP2D6 INHIBITION BY BUPROPION AND ITS METABOLITES IS STEREOSPECIFIC AND CIRCULATING METABOLITES ACCURATELY PREDICT CLINICAL BUPROPION-CYP2D6 INTERACTION.

被引：0
|
作者：
Tanaudommongkon, I. [1 ]
Gufford, B. T. [1 ]
Lu, J. B. [1 ]
Desta, Z. [1 ]
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-111
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [2] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
    Sager, Jennifer E.
    Tripathy, Sasmita
    Price, Lauren S. L.
    Nath, Abhinav
    Chang, Justine
    Stephenson-Famy, Alyssa
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2017, 123 : 85 - 96
  • [3] DOSE DEPENDENT CYP2D6 INHIBITION BY BUPROPION AND LEVOMEPROMAZINE
    Haslemo, T.
    Arnestad, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 7
  • [4] INHIBITION OF CYP2D6 BY BUPROPION IN HEALTHY VOLUNTEERS.
    Duong, A.
    Gufford, B.
    Liu, S.
    Benson, E.
    Lu, J.
    Stoughton, C.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S71 - S71
  • [5] Bupropion SR a potent inhibitor of CYP2D6
    Reactions Weekly, 2005, 1063 (1) : 5 - 5
  • [6] Bupropion plasma levels and CYP2D6 phenotype
    Pollock, BG
    Sweet, RA
    Kirshner, M
    Reynolds, CF
    THERAPEUTIC DRUG MONITORING, 1996, 18 (05) : 581 - 585
  • [7] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)
    Sager, Jennifer E.
    Tripathy, Sasmita
    Price, Lauren S. L.
    Nath, Abhinav
    Chang, Justine
    Stephenson-Famy, Alyssa
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2021, 183
  • [8] Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression
    Hole, Kristine
    Arnestad, Marianne
    Molden, Espen
    Haslemo, Tore
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (03) : 281 - 285
  • [9] Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
    Molden, E
    Johansen, PW
    Boe, GH
    Bergan, S
    Christensen, H
    Rugstad, HE
    Rootwelt, H
    Reubsaet, L
    Lehne, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 333 - 342
  • [10] Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol
    Shin, JG
    Kane, K
    Flockhart, DA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (01) : 45 - 52
12345